|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
In vivo, using age-matched transgenic adenocarcinoma of mouse prostate (TRAMP) mice at different stages of prostate cancer [prostatic intraepithelial neoplasia, PIN; well-differentiated adenocarcinoma, WD; and poorly differentiated adenocarcinoma, PD], the expression of beta1A and of IGF-IR was studied. beta1A and IGF-IR expression levels were concurrently up-regulated in high PIN and WD, whereas their expression did not correlate in late-stage PD.
|
16061650 |
2005 |
|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer.<b>Experimental Design:</b> By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, <i>in vitro</i> macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer.<b>Results:</b> Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages.
|
30012567 |
2018 |
|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
PIN has a high predictive value as a marker for adenocarcinoma.
|
8700801 |
1996 |
|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
Prostates of the TG mice showed an increased size and changes in stromal and epithelial morphology progressing from atypia and prostatic intraepithelial neoplasia (mouse PIN, mPIN) lesions to tumors with highly variable phenotype bearing features of adenocarcinoma, carcinosarcoma, and sarcoma.
|
21076617 |
2010 |
|
Adenocarcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
However, quantitative evaluation of prostatic lesions demonstrated significantly suppression of sequential progression from PIN to adenocarcinoma in a dose-dependent manner, along with clear activation of caspases 3 and 7 in the ventral lobe in both experiments.
|
19143023 |
2009 |
|
Adenocarcinoma of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prolonged treatment of adult rodents with estrogens along with androgens also leads to epithelial metaplasia, PIN-like lesions and even adenocarcinoma of prostate speaking for the role of estrogen in prostate cancer development.
|
15663993 |
2004 |
|
Adenoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Partial (1%-10%) and extensive (10%-100%) DLC-1 promoter methylations were observed in 10% and 0% of normal mucosa, 46% and 14% of adenomas, and 60% and 36% of CRCs, respectively.
|
23509688 |
2013 |
|
Adult Burkitt Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DLC-1 expression was not detectable in two human BL cell lines, Raji and Daudi, by reverse transcription-PCR.
|
20882354 |
2011 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
DLC-1 (deleted in liver cancer) gene is frequently deleted in hepatocellular carcinoma.
|
12813468 |
2003 |
|
Adult Liver Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
We investigated the expression and deletion of DLC-1 (frequently deleted in liver cancer gene), first reported in 1998 and having a high homology with rat p122RhoGAP in hepatocellular carcinoma (HCC).
|
11118037 |
2000 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
DLC-1 may be a tumor suppressor gene in liver cancer as well as in other cancers.
|
9605766 |
1998 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The DLC-1 gene encoding a regulator of the Rho family of small GTPases is altered in breast, prostate, colon, and liver cancer and has several characteristics of a tumor suppressor gene.
|
12792785 |
2003 |
|
Adult Liver Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Further, the miRNA-target gene network analysis displayed that the deleted in liver cancer (DLC-1) gene, an important negative regulator for cell motility, was potentially targeted by several differentially expressed miRNAs in HBc-introduced cells.
|
28982593 |
2018 |
|
Adult Liver Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
The deleted in liver cancer (DLC-1) gene at chromosome 8p21-22 is altered mainly by genomic deletion or aberrant promoter methylation in a large number of human cancers such as breast, liver, colon and prostate and is known to have an inhibitory effect on breast and liver tumor cell growth.
|
14661059 |
2004 |
|
Adult Liver Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The SH2 domain in tensin family member c-ten requires R474 to bind a RhoGAP called DLC-1 (deleted in liver cancer).
|
19826001 |
2009 |
|
Adult Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Constitutive loss of Asciz or Dynll1 delayed lymphoma development in Eμ-Myc mice, and induced deletion of Asciz in established lymphomas extended the survival of tumor-bearing mice.
|
26832406 |
2016 |
|
Adult Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene.
|
20882354 |
2011 |
|
Allergic rhinitis (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
DLC (i.v.), given after an allergen challenge, improved Th1 cytokines level and restrained Th2 responses alleviating the symptoms of AR.
|
26155922 |
2015 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have confirmed the involvement of specific proteins previously associated with ALS (Galectin 2 (<i>LGALS3</i>), Transthyretin (<i>TTR</i>), Protein S100-A6 (<i>S100A6</i>), and Protein S100-A11 (<i>S100A11</i>)) and have shown the involvement of proteins not previously described in the ALS context (Methanethiol oxidase (<i>SELENBP1</i>), Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (<i>PIN-1</i>), Calcyclin-binding protein (<i>CACYBP</i>) and Rho-associated protein kinase 2 (<i>ROCK2</i>)).
|
30577465 |
2018 |
|
Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found increased expression of DLC-1 in stiffness-associated diseases like atherosclerosis and pulmonary arterial hypertension.
|
30231995 |
2018 |
|
Atherosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found increased expression of DLC-1 in stiffness-associated diseases like atherosclerosis and pulmonary arterial hypertension.
|
30231995 |
2018 |
|
B-Cell Lymphomas
|
0.020 |
Biomarker
|
group |
BEFREE |
Finally, we found that the ASCIZ-DYNLL1 axis was also required for the early-juvenile development of aggressive MYC-driven and p53-deficient B cell lymphomas.
|
28922373 |
2017 |
|
B-Cell Lymphomas
|
0.020 |
Biomarker
|
group |
BEFREE |
The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.
|
26832406 |
2016 |
|
Benign Prostatic Hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
No association was found for correlation of PCA3 score change with age >65 years (p=0.975), family history of prostate cancer (p=0.796), positive DRE (p=0.179), use of 5-alpha-reductase inhibitors (p=0.793) and BPH/prostatitis/HG-PIN/ASAP diagnosis (p=0.428).
|
25862908 |
2015 |
|
Brain Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Induction of protein inhibitor of neuronal nitric oxide synthase/cytoplasmic dynein light chain following cerebral ischemia.
|
9522364 |
1998 |